Poster Presentations to Focus on Reqorsa as a
Potential Treatment for Ras Inhibitor Resistant Lung Cancer,
Mesothelioma and Glioblastoma
AUSTIN,
Texas, Sept. 9, 2024 /PRNewswire/ -- Genprex,
Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage
gene therapy company focused on developing life-changing therapies
for patients with cancer and diabetes, today announced that its
research collaborators were selected to present at the upcoming
2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics being held October 23-25,
2024 in Barcelona, Spain.
The collaborators will present posters on positive preclinical data
from studies of its lead drug candidate,
Reqorsa® Gene Therapy (quaratusugene ozeplasmid),
for the treatment of Ras inhibitor resistant lung cancer,
mesothelioma and glioblastoma.
"We are very pleased that these studies with our academic
partners have been selected for presentation, which expands the
growing body of preclinical evidence supporting REQORSA's potential
to treat a variety of cancers," said Ryan
Confer, President and Chief Executive Officer at Genprex.
"We look forward to these presentations next month which will share
the compelling data that support the potential for new clinical
studies evaluating Reqorsa as a potential treatment for additional
types of lung cancer, mesothelioma and glioblastoma."
Featured Genprex-supported posters to be presented at the 2024
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer
Therapeutics include:
Title: "TUSC2 gene therapy in KRASG12C mutant NSCLC
overcomes acquired resistance to sotorasib"
Collaborator: The University of
Texas MD Anderson Cancer Center
Catalog Number: 384
Presentation Number: PB372
Title: "TUSC2 Suppresses Tumorigenic Properties in
Malignant Pleural Mesothelioma Cells"
Collaborator: New York
University Langone Health
Catalog Number: 364
Presentation Number: PB352
Title: "Efficacy of Quaratusugene Ozeplasmid TUSC2 Gene
Therapy in Glioblastoma"
Collaborator: The University of Texas
Health Science Center at Houston
Catalog Number: 130
Presentation Number: PB118
Genprex has filed two provisional patent applications based on
data from two of the presentations. One application involves using
REQORSA to treat mesothelioma and the other to treating
glioblastoma. Genprex is a co-owner of the applications along with
the respective institutions. TUSC2 is the tumor suppressor gene
used in REQORSA. REQORSA consists of a TUSC2 gene expressing
plasmid encapsulated in non-viral lipid-based nanoparticles in
a lipoplex form (the Company's Oncoprex®
Delivery System), which has a positive charge. REQORSA is injected
intravenously and specifically targets cancer cells. REQORSA is
designed to deliver the functioning TUSC2 gene to negatively
charged cancer cells while minimizing uptake by normal tissue.
Laboratory studies conducted at MD Anderson show that the
uptake of TUSC2 in tumor cells in vitro after REQORSA treatment
was 10 to 33 times the uptake in normal cells.
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused
on developing life-changing therapies for patients with cancer and
diabetes. Genprex's technologies are designed to administer
disease-fighting genes to provide new therapies for large patient
populations with cancer and diabetes who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to develop drug candidates to further its pipeline of
gene therapies in order to provide novel treatment approaches.
Genprex's oncology program utilizes its systemic, non-viral
Oncoprex® Delivery System which encapsulates the
gene-expressing plasmids using lipid-based nanoparticles in a
lipoplex form. The resultant product is administered intravenously,
where it is taken up by tumor cells that then express tumor
suppressor proteins that were deficient in the tumor. The Company's
lead product candidate, Reqorsa® Gene Therapy
(quaratusugene ozeplasmid), is being evaluated in two clinical
trials as a treatment for NSCLC and SCLC. Each of Genprex's lung
cancer clinical programs has received a Fast Track Designation from
the FDA for the treatment of that patient population, and Genprex's
SCLC program has received an FDA Orphan Drug Designation. Genprex's
diabetes gene therapy approach is comprised of a novel infusion
process that uses an AAV vector to deliver Pdx1 and MafA genes
directly to the pancreas. In models of Type 1 diabetes, GPX-002
transforms alpha cells in the pancreas into functional beta-like
cells, which can produce insulin but may be distinct enough from
beta cells to evade the body's immune system. In a similar
approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at
play, is believed to rejuvenate and replenish exhausted beta
cells.
Interested investors and shareholders are encouraged to sign up
for press releases and industry updates by visiting
the Company Website, registering for Email
Alerts and by following Genprex on Twitter, Facebook and
LinkedIn.
Cautionary Language Concerning Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These forward-looking statements are made on the basis of
the current beliefs, expectations and assumptions of management,
are not guarantees of performance and are subject to significant
risks and uncertainty. These forward-looking statements should,
therefore, be considered in light of various important factors,
including those set forth in Genprex's reports that it files from
time to time with the Securities and Exchange Commission and which
you should review, including those statements under "Item 1A – Risk
Factors" in Genprex's Annual Report on Form 10-K for the year ended
December 31, 2023.
Because forward-looking statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding:
Genprex's ability to advance the clinical development,
manufacturing and commercialization of its product candidates in
accordance with projected timelines and specifications; the timing
and success of Genprex's clinical trials and regulatory approvals;
the effect of Genprex's product candidates, alone and in
combination with other therapies, on cancer and diabetes; the
effects of any strategic research and development prioritization
initiatives, and any other strategic alternatives or other efforts
that Genprex takes or may take in the future that are aimed at
optimizing and re-focusing Genprex's diabetes, oncology and/or
other clinical development programs including prioritization of
resources, and the extent to which Genprex is able to implement
such efforts and initiatives successfully to achieve the desired
and intended results thereof; Genprex's future growth and financial
status, including Genprex's ability to maintain compliance
with the continued listing requirements of The Nasdaq Capital
Market and to continue as a going concern and to obtain capital to
meet its long-term liquidity needs on acceptable terms, or at all;
Genprex's commercial and strategic partnerships, including those
with its third party vendors, suppliers and manufacturers and their
ability to successfully perform and scale up the manufacture of its
product candidates; and Genprex's intellectual property and
licenses.
These forward-looking statements should not be relied upon as
predictions of future events and Genprex cannot assure you that the
events or circumstances discussed or reflected in these statements
will be achieved or will occur. If such forward-looking statements
prove to be inaccurate, the inaccuracy may be material. You should
not regard these statements as a representation or warranty by
Genprex or any other person that Genprex will achieve its
objectives and plans in any specified timeframe, or at all. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Genprex disclaims any obligation to publicly update or release any
revisions to these forward-looking statements, whether as a result
of new information, future events or otherwise, after the date of
this press release or to reflect the occurrence of unanticipated
events, except as required by law.
Genprex, Inc.
(877) 774-GNPX (4679)
GNPX Investor
Relations
investors@genprex.com
GNPX Media Contact
Kalyn
Dabbs
media@genprex.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/genprex-collaborators-to-present-positive-preclinical-data-on-the-use-of-reqorsa-gene-therapy-at-the-2024-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics-302241636.html
SOURCE Genprex, Inc.
